Market revenue in 2023 | USD 54.8 million |
Market revenue in 2030 | USD 142.1 million |
Growth rate | 14.6% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Kits & Reagents, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 57.66% in 2023. Horizon Databook has segmented the UK mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing investments in developing innovative cell culture solutions and emerging regional players with advanced solutions are anticipated to significantly boost the UK’s market growth. The UK has been at the forefront of regenerative medicine and cell therapy research. Clinical trials and translational studies focusing on cell-based therapies, including stem cell-based treatments, are actively conducted in the country.
With continuous innovation and research being done within the country, there has been a continuous demand for mycoplasma testing products & services. For instance, in September 2023, FUJIFILM Diosynth Biotechnologies announced that they had completed a new viral vector gene therapy manufacturing plant in Darlington, UK.
The plant would be used for manufacturing early-stage viral vectors. This creates opportunities for companies involved in cell culture to provide specialized culture media, growth factors, and other cell culture-related products & services. For instance, in March 2021, CN Bio received Innovate UK grant for testing human-relevant, multi and single-organ models for COVID19 research, including using 3D cell culture for lungs.
Horizon Databook provides a detailed overview of country-level data and insights on the UK mycoplasma testing market , including forecasts for subscribers. This country databook contains high-level insights into UK mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account